289 related articles for article (PubMed ID: 20823808)
21. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
Iagaru A; Quon A; McDougall IR; Gambhir SS
Clin Nucl Med; 2006 Dec; 31(12):754-60. PubMed ID: 17117068
[TBL] [Abstract][Full Text] [Related]
22. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
Ho CL; Chen S; Yeung DW; Cheng TK
J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
[TBL] [Abstract][Full Text] [Related]
23. Nuclear Medicine in Pediatric and Adolescent Tumors.
Kiratli PÖ; Tuncel M; Bar-Sever Z
Semin Nucl Med; 2016 Jul; 46(4):308-23. PubMed ID: 27237441
[TBL] [Abstract][Full Text] [Related]
24. Whole-body PET/CT with 11C-meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with 123I-MIBG SPECT/CT.
Franzius C; Hermann K; Weckesser M; Kopka K; Juergens KU; Vormoor J; Schober O
J Nucl Med; 2006 Oct; 47(10):1635-42. PubMed ID: 17015899
[TBL] [Abstract][Full Text] [Related]
25. FDG PET/MR in initial staging of sarcoma: Initial experience and comparison with conventional imaging.
Platzek I; Beuthien-Baumann B; Schramm G; Maus J; Laniado M; Kotzerke J; van den Hoff J; Schuler M
Clin Imaging; 2017; 42():126-132. PubMed ID: 27951459
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies.
Tatsumi M; Miller JH; Wahl RL
J Nucl Med; 2007 Dec; 48(12):1923-31. PubMed ID: 18056332
[TBL] [Abstract][Full Text] [Related]
27. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
[TBL] [Abstract][Full Text] [Related]
28. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography in recurrent hepatoblastoma.
Philip I; Shun A; McCowage G; Howman-Giles R
Pediatr Surg Int; 2005 May; 21(5):341-5. PubMed ID: 15834579
[TBL] [Abstract][Full Text] [Related]
30. Prospective study of [18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck.
Ng SH; Yen TC; Chang JT; Chan SC; Ko SF; Wang HM; Lee LY; Kang CJ; Wong AM; Liao CT
J Clin Oncol; 2006 Sep; 24(27):4371-6. PubMed ID: 16983105
[TBL] [Abstract][Full Text] [Related]
31. Integrated FDG-PET-CT: its role in the assessment of bone and soft tissue tumors.
Bischoff M; Bischoff G; Buck A; von Baer A; Pauls S; Scheffold F; Schultheiss M; Gebhard F; Reske SN
Arch Orthop Trauma Surg; 2010 Jul; 130(7):819-27. PubMed ID: 19636577
[TBL] [Abstract][Full Text] [Related]
32. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
33. 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours.
Nanni C; Rubello D; Castellucci P; Farsad M; Franchi R; Rampin L; Gross MD; Al-Nahhas A; Fanti S
Biomed Pharmacother; 2006 Nov; 60(9):593-606. PubMed ID: 16978824
[TBL] [Abstract][Full Text] [Related]
34. Molecular imaging of sarcomas with FDG PET.
Mendoza H; Nosov A; Pandit-Taskar N
Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
[TBL] [Abstract][Full Text] [Related]
35. Dual modality of 18F-fluorodeoxyglucose-positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary.
Freudenberg LS; Fischer M; Antoch G; Jentzen W; Gutzeit A; Rosenbaum SJ; Bockisch A; Egelhof T
Med Princ Pract; 2005; 14(3):155-60. PubMed ID: 15863988
[TBL] [Abstract][Full Text] [Related]
36. Roles of positron emission tomography with fluorine-18-deoxyglucose in the detection of local recurrent and distant metastatic sarcoma.
Johnson GR; Zhuang H; Khan J; Chiang SB; Alavi A
Clin Nucl Med; 2003 Oct; 28(10):815-20. PubMed ID: 14508272
[TBL] [Abstract][Full Text] [Related]
37. Isolated thymic Langerhans cell histiocytosis discovered on F-18 fluorodeoxyglucose positron emission tomography/computed tomography (F-18 FDG PET/CT).
Turpin S; Carret AS; Dubois J; Buteau C; Patey N
Pediatr Radiol; 2015 Nov; 45(12):1870-3. PubMed ID: 26155984
[TBL] [Abstract][Full Text] [Related]
38. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
39. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
